{
    "title": "Reverse Voxsplaining: Brand-Name Drugs",
    "date": "September 7, 2016",
    "links": [
        "http://www.vox.com/2016/8/31/12729482/fda-epipen-pharma-regulations",
        "http://www.nber.org/papers/w12676",
        "https://healtheconomicsreview.springeropen.com/articles/10.1186/s13561-014-0023-5",
        "https://economics.stanford.edu/sites/default/files/publications/kutyavina_hthesis2010.pdf",
        "http://economics.mit.edu/files/4464",
        "http://www.nber.org/papers/w14041",
        "http://www.cluteinstitute.com/ojs/index.php/JABR/article/view/2131",
        "http://download.clib.psu.ac.th/datawebclib/e_resource/trial_database/WileyInterScienceCD/pdf/HEC/HEC_2.pdf",
        "https://www.cambridge.org/core/journals/journal-of-financial-and-quantitative-analysis/article/pharmaceutical-randd-spending-and-threats-of-price-regulation/1ADD6875F2AA693D267052C2AE0AA6AF",
        "http://www.nkd-group.com/ghdash/mba555/PDF/ConsumerDemandPriceControl.pdf",
        "https://www.researchgate.net/profile/Daniel_Carpenter2/publication/43201263_US_pharmaceutical_innovation_in_an_international_context/links/0deec537e2b970043b000000.pdf",
        "http://www.rand.org/pubs/research_briefs/RB9412.html",
        "https://www.census.gov/newsroom/cspan/pop_proj/20121214_cspan_popproj.pdf",
        "http://ec.europa.eu/economy_finance/structural_reforms/ageing/demography/index_en.htm",
        "https://slatestarcodex.com/2013/12/08/a-something-sort-of-like-left-libertarianism-ist-manifesto/",
        "http://www.bloomberg.com/news/articles/2015-06-01/hepatitis-cruise-india-trips-among-plans-to-save-on-1-000-pill",
        "http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm",
        "https://slatestarcodex.com/2015/04/30/prescriptions-paradoxes-and-perversities/",
        "http://carlatpsychiatry.blogspot.com/2008/03/top-5-reasons-to-forget-about-pristiq.html",
        "http://mentalhealthdaily.com/2014/08/30/most-popular-antidepressants-in-2014-cymbalta-pristiq-viibryd/",
        "http://www.aahs.org/medstaff/wp-content/uploads/PharmaceuticalJAMA2016.pdf",
        "http://www.pharmacychecker.com/brand/price-comparison/pristiq/50+mg/",
        "http://www.healthline.com/health-news/allergy-drug-could-best-sovaldi-harvoni-040815"
    ],
    "url": "https://slatestarcodex.com/2016/09/07/reverse-voxsplaining-brand-name-drugs/",
    "summary": "Key ideas:\n- The US has created a favorable regulatory system that allows pharmaceutical companies to charge high prices for their products.\n- The US lets drug companies pick their own prices and has allowed roadblocks to stand in the way of generic drug makers who want to enter.\n- Brand name drugs are the reason for America's higher per-capita drug spending than other countries.\n- Brand-name drugs are overpriced intentionally to encourage research, and high generic drug pricing is due to poor regulatory oversight.\n- The high cost of certain brand-name drugs can be mitigated by switching to heavily-competitive generic drugs.\n- The current regulatory system may impede drug innovation and lead to increased drug costs.\n- Medical education and economics can be improved to prevent doctors from being bamboozled into prescribing expensive brand-name drugs.\n\nKey learnings:\n- Greater use of generic drugs is widely accepted as a way to drive down drug spending.\n- Drugs under patent are the true source of high American drug costs.\n- Some people would say that high brand-name drug pricing is worth the benefit of encouraging more drug development, while others would say that it isn't.\n- Number of competing companies is strongly correlated with the cost of generics.\n- Expensive brand-name drugs can often be replaced by generic equivalents with almost identical functionality.\n- There is potential for competition and innovation to increase with looser FDA regulatory requirements.\n\nKey questions:\n- Does brand name drug pricing encourage enough research and innovation to justify the high costs?\n- What is the best way to regulate drug prices in a way that balances cost with innovation and accessibility?\n- How can the regulatory regime for generic drugs be improved to drive down prices?\n- Why does the United States allow heavily inflated prices for drugs like Pristiq, relative to other countries?\n- What strategies can be put in place to ensure that poor patients have access to life-saving drugs?\n- How can we balance the need for innovation with the need for medication affordability?\n"
}